Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: A proton MR spectroscopic imaging study

American Journal of Neuroradiology

Volumn 33, Issue 11, 2012, Pages 2095-2102

  Jeon, J Y ^a   Kovanlikaya, I ^a   Boockvar, J A ^a   Mao, X ^b   Shin, B ^a   Burkhardt, J K ^a   Kesavabhotla, K ^a   Christos, P ^b   Riina, H ^c   Shungu, D C ^b   Tsiouris, A J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHOLINE; CREATINE; LACTIC ACID;

ADULT; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING EQUIPMENT; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PROTON NUCLEAR MAGNETIC RESONANCE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASPARTIC ACID; BRAIN; BRAIN NEOPLASMS; CEREBRAL ARTERIES; CHOLINE; FEMALE; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROTONS; TREATMENT OUTCOME;

EID: 84871775462     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3091     Document Type: Article

References (28)

1. Stupp R. Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66
2. Abraham J. Bevacizumab in recurrent glioblastoma. Commun Oncol 2009;6:397-400
3. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14:1131-38
4. Mukherji SK. Bevacizumab (Avastin). AJNR Am J Neuroradiol 2010;31:235-36
5. Boockvar JA, Tsiouris AJ, Hofstetter CP, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. J Neurosurg 2011;114:624-32
6. Riina HA, Fraser JF, Fralin S, et al. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol 2009;8:145-50
7. Burkhardt J-K, Riina HA, Shin BJ, et al. Intra-arterial delivery of bevacizumab after blood brain barrier disruption for the treatment of recurrent glioblastoma: progression free survival and overall survival. World Neurosurg 2012;77:130-34
8. Fischer I, Cunliffe CH, Bollo RJ, et al. High-grade glioma before and after treatment with radiation and Avastin: initial observations. J Neurooncol 2008;10:700-08
9. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-60 (Pubitemid 43739717)
10. Wagle N, Nghiemphu L, Lai A, et al. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmacogenomics Pers Med 2010;3:79-85
11. de Groot JF, Yung WKA. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008;14:279-85
12. Balmaceda C, Critchell D, Mao X, et al. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol 2006;76:185-91 (Pubitemid 43125747)
13. Smith EA, Carlos RC, Junck LR, et al. Developing a clinical decision model:MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009;192:W45-52
14. Weybright P, Sundgren PC, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 2005;185:1471-76
15. Srinivasan R, Phillips JJ, VandenBerg SR, et al. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neurooncol 2010;12:1152-61
16. Fan, G. Comments and controversites: magnetic resonance spectroscopy and gliomas. Cancer Imaging 2006;6:113-15
17. Wen PY, MacDonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J ClinOncol 28:1963-72
18. Duyn JH, Gillen J, Sobering G, et al. Multisection proton MR spectroscopic imaging of the brain. Radiology 1993;188:277-82 (Pubitemid 23183139)
19. Al-Okaili RN, Krejza J, Wang S, et al. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 2006;26:S173-89
20. Lin A, Bluml S, Mamelak AN. Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J Neurooncol 1999;45:69-81 (Pubitemid 30142443)
21. Lin A, Ross BD, Harris K, et al. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005;2:197-214 (Pubitemid 40471432)
22. McKnight TR, con dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002;97:794-802
23. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, et al. Pseudoprogression and pseudoreponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011;32:1978-85
24. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010;12:26-33
25. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80 (Pubitemid 20195640)
26. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;227:4733-40
27. Dhermain FG, Hau P, Lanferman H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9:906-20
28. Gerstner ER, Sorensen AG, Jain RK, et al. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 2008;21:728-35